Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 17/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 16/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8400863 | 0.83 | SLC22A6 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL8709228 | 0.83 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6833575 | 0.80 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6836050 | 0.80 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL6836055 | 0.80 | HSP90AB1 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL23223510 | 0.77 | FAP (0.48) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL17194161 | 0.77 | FAP (0.48) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL14621498 | 0.76 | SLC22A6 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL20012285 | 0.75 | HPRT1 (0.45) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL10511149 | 0.74 | AHCY (0.57) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | AVENTIS PHARMACEUTICALS INC. | 2004-04-08 | — | — | US | disclosed |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | CASARA PATRICK (FR) | 2003-01-02 | — | — | US | disclosed |
| US-5922696-A | VIRICIDES AGAINST DNA VIRUSES, RETROVIRUSES AND VIRUSES INVOLVED IN TUMOR FORMATION, CYTOMEGALOVIRUS, VARICELLA-ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HUMAN IMMUNODEFICIENCY VIRUSES | MERRELL PHARMACEUTICALS INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5817647-A | VIRICIDES; ANTITUMOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0701562-B1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL PHARMA INC (US) | 1997-06-18 | — | — | EP | disclosed |
| EP-0701562-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994022882-A1 | UNSATURATED PHOSPHONATES DERIVATIVES OF PURINES AND PYRIMIDINES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0618214-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068111-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | HSP90AB1 4181/4885HSP90AA1 4008/4885HDAC6 4823/4885 |
| US-20030004345-A1 | Unsaturated phosphonate derivatives of purines and pyrimidines | TYMP, NUDT1, PNP | HSP90AB1 4181/4885HSP90AA1 4008/4885HDAC6 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.